<?xml version="1.0" encoding="utf-8"?>
<export-example>
  <doc>
    <id>1850</id>
    <completedYear/>
    <publishedYear>2023</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber>101</pageNumber>
    <edition/>
    <issue/>
    <volume/>
    <type>bachelorthesis</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2023-12-18</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>2023-09-11</thesisDateAccepted>
    <title language="eng">Targeted therapy to overcome the blood-brain barrier in treating Glioblastoma</title>
    <abstract language="eng">Glioblastoma represents a challenge in oncology, characterized by its aggressive nature and resistance to conventional therapies. This thesis conducts a comprehensive examination of Glioblastoma, with a primary focus on advancing therapeutic strategies through precision medicine and sophisticated drug delivery mechanisms. The inquiry starts with an exhaustive analysis of the intricate blood-brain barrier, a vital neurovascular interface critical for understanding drug delivery complexities to the central nervous system. Subsequently, the study delves into Glioblastoma, elucidating its etiological foundations, molecular intricacies, clinical presentations, and existing treatment paradigms.&#13;
The core of this research centers on the exploration of state-of-the-art targeted therapies, encompassing molecular-level targeting, immunotherapeutic modalities, and synergistic therapeutic approaches. It dissects a range of strategies aimed at enhancing drug delivery, including chemical disruption techniques, innovative delivery methodologies, and bioengineered approaches.&#13;
Furthermore, it underscores the transformative potential of nanotechnology, emphasizing nanocarriers as precision tools poised to revolutionize GBM therapy.&#13;
The literature review is conducted meticulously, drawing from renowned databases like PubMed, NCBI, NIH/National Cancer Institute, JSTOR, and BioMed Central. Additionally, reputable national and international health institute websites, along with carefully selected books from the campus library, contribute to the diverse and robust foundation of credible information.&#13;
The discussion segment dissects the challenges inherent in GBM targeted treatment, underscores the burgeoning domain of precision medicine, highlights the paradigm-shifting role of theranostics,&#13;
and outlines a roadmap for future prospects in this intricate landscape.</abstract>
    <identifier type="urn">urn:nbn:de:hbz:1383-opus4-18504</identifier>
    <enrichment key="opus.source">publish</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">true</enrichment>
    <licence>CC BY-NC-ND 4.0 International - Namensnennung-Nicht kommerziell-Keine Bearbeitungen</licence>
    <author>Fatma Belkhodja</author>
    <collection role="institutes" number="">Fakultät Life Sciences</collection>
    <thesisPublisher>Hochschule Rhein-Waal</thesisPublisher>
    <thesisGrantor>Hochschule Rhein-Waal</thesisGrantor>
    <file>https://opus4.kobv.de/opus4-rhein-waal/files/1850/Belkhodja.BSc.thesis.pdf</file>
  </doc>
  <doc>
    <id>1814</id>
    <completedYear/>
    <publishedYear>2023</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber>99</pageNumber>
    <edition/>
    <issue/>
    <volume/>
    <type>bachelorthesis</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2023-10-03</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>2023-09-15</thesisDateAccepted>
    <title language="eng">The use of biocatalysis in the diagnosis and treatment of colorectal cancer (CRC)</title>
    <abstract language="eng">Colorectal cancer is a significant global health burden. Early-stage colorectal cancer is asymptomatic, which, coupled with the fact that later stages of CRC have a very low prognosis, and that current methods of diagnosis and treatment significantly impact the patient, exploring alternate ways to diagnose and treat CRC is vital.&#13;
Biocatalysis is the use of naturally found catalysts such as nanozymes and enzymes in order to catalyze reactions. Due to their characteristics and uses, biocatalysts are seen as promising alternatives to current methods of CRC diagnosis and therapy.&#13;
This research-based bachelor thesis aims to summarize and analyze current traditional and biocatalytic methods that exist to diagnose and treat CRC, in order to seek the potential of biocatalysis in this field, as well as discuss its current state and its future in comparison to currently implemented methods. It provides an extensive overview of traditional and biocatalytic approaches to diagnosis and therapy, considering important factors such as efficacy, sensitivity, selectivity, cost, and safety.&#13;
The thesis also delves into the use of biocatalysis for important points such as the early diagnosis of CRC, and the challenges faced during development, regulation, and monetary concerns. Through careful analysis of the strengths and limitations of techniques in the field, as well as personal opinions on the future of research, conclusions on given hypotheses regarding biocatalysis in CRC diagnosis and therapies were presented and included strong support for the unquestionable potential of biocatalysis use in cancer healthcare, while highlighting possibilities to tap into that potential by scrutinizing their equally as unquestionable current limitations.&#13;
Overall, this thesis aspires to contribute, on however minuscule a scale, towards the advancement of CRC diagnosis and therapy approaches, with the ambition of improving patient care and prognosis, as well as quality of life for those struggling or who will struggle in the future with the disease, together with their kin who are profoundly affected as well.</abstract>
    <identifier type="urn">urn:nbn:de:hbz:1383-opus4-18147</identifier>
    <enrichment key="opus.source">publish</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">true</enrichment>
    <licence>CC BY-NC-ND 4.0 International - Namensnennung-Nicht kommerziell-Keine Bearbeitungen</licence>
    <author>Basil Mazen Hammoudeh</author>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Colorectal cancer</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Cancer</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Biocatalysis</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Enzymes</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Diagnosis</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Therapy</value>
    </subject>
    <collection role="institutes" number="">Fakultät Life Sciences</collection>
    <thesisPublisher>Hochschule Rhein-Waal</thesisPublisher>
    <thesisGrantor>Hochschule Rhein-Waal</thesisGrantor>
    <file>https://opus4.kobv.de/opus4-rhein-waal/files/1814/BasilHammoudeh_Thesis_FINAL_SIGNED.pdf</file>
  </doc>
  <doc>
    <id>1856</id>
    <completedYear/>
    <publishedYear>2023</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber>70</pageNumber>
    <edition/>
    <issue/>
    <volume/>
    <type>bachelorthesis</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2023-12-26</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>2023-10-27</thesisDateAccepted>
    <title language="eng">Generation and expression of a mutated murine tRNA-guanine transglycosylase variant</title>
    <abstract language="eng">Translation of messenger RNA carrying the nucleic code for protein synthesis is one of the vital bioprocesses of living organisms. This translation is mediated by transfer RNA, which allocates specific amino acids to the growing chain by decoding the genetic code. The tRNAs with the G34U35N36 anticodon sequence are recognised by an enzyme called tRNA-guanine transglycosylase, which catalyses the exchange of guanine with queuine. TGT enzyme is found in all three domains of life and is involved in post-transcriptional modification. TGT is of keen interest in the development of therapeutics against shigellosis, since the genetic inactivation of TGT leads to decreased pathogenicity in Shigella. For understanding the differences between bacterial and eukaryotic TGT, studies have been performed in the past, which show remarkable resemblance. On the contrary, some pronounced structural contrast can also be observed. One prominent difference is that the bacterial TGT contains a short turn of three amino acids, whereas, in eukaryotes, this turn is replaced by an extended loop of more than 45 amino acids. The function of this loop in eukaryotic TGT is not known. The loop is a highly flexible region and, thus, is not structurally solved. To elucidate the function of this loop, a TGT mutant lacking this loop was generated, expressed and purified. TGT mutant was expressed in different bacterial cell strains. For the purification, different chromatography techniques were utilised. The mutation resulted in a low yield of the protein in comparison to the wild-type TGT. This leads to the inference that the loop influences the physicochemical characteristics of the protein.</abstract>
    <identifier type="urn">urn:nbn:de:hbz:1383-opus4-18560</identifier>
    <enrichment key="opus.source">publish</enrichment>
    <licence>CC BY-NC 4.0 International - Namensnennung-Nicht kommerziell</licence>
    <author>Muhammad Imran Mumtaz</author>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>RNA-guanine transglycosylase</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Generation</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Expression</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Queuine</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Protein purification</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Chromatography</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Site-directed mutagenesis</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Protein mutation</value>
    </subject>
    <collection role="ddc" number="57">Biowissenschaften; Biologie</collection>
    <collection role="institutes" number="">Fakultät Life Sciences</collection>
    <thesisPublisher>Hochschule Rhein-Waal</thesisPublisher>
    <thesisGrantor>Hochschule Rhein-Waal</thesisGrantor>
    <file>https://opus4.kobv.de/opus4-rhein-waal/files/1856/Mumtaz_MurineQTRT2.pdf</file>
  </doc>
  <doc>
    <id>1673</id>
    <completedYear/>
    <publishedYear>2023</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber>80</pageNumber>
    <edition/>
    <issue/>
    <volume/>
    <type>bachelorthesis</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2023-02-06</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>2022-12-27</thesisDateAccepted>
    <title language="eng">Evaluating the potential of mRNA vaccines for human rabies</title>
    <abstract language="eng">To this date, rabies is still one of the most fatal diseases worldwide and generates at least 59,000 deaths per year. Although current vaccines are safe and effective, RNA technology proposes improved vaccines that are potentially able to facilitate eradication of rabies until 2030. In this review, RNA vaccine candidates are evaluated for their potential to be effective against rabies and to be implemented in immunization programs. To understand the relevance of disease prevention, rabies virus and its function in the body is clarified. RNA technology is explained to comprehend its mode of action in the human immune system and its potential to be a vaccine platform. Comparison to existing vaccines showed advantages in several characteristics that are relevant for vaccine approval. RNA vaccines scored better in efficacy, stability, production, and dosing, but there is still room for improvements in terms of safety and tolerability. Theoretical potential is proven, but practical translation of RNA vaccines into clinical candidates requires more attention, as safety and tolerability are the leading limiting factor for approval of any new drug or vaccine. Producing a safe, stable and effective RNA vaccine does not necessarily ensure less rabies deaths, because rabies control strategies heavily rely on proper funding and availability in these rabies endemic region. Nonetheless, RNA vaccine technology offers potential solutions for the elimination of rabies.</abstract>
    <identifier type="urn">urn:nbn:de:hbz:1383-opus4-16737</identifier>
    <enrichment key="opus.source">publish</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">true</enrichment>
    <licence>Bestimmungen des deutschen Urheberrechts</licence>
    <author>Ole Waller</author>
    <collection role="institutes" number="">Fakultät Life Sciences</collection>
    <thesisPublisher>Hochschule Rhein-Waal</thesisPublisher>
    <thesisGrantor>Hochschule Rhein-Waal</thesisGrantor>
    <file>https://opus4.kobv.de/opus4-rhein-waal/files/1673/Bachelorthesis_OWaller_25337.pdf</file>
  </doc>
  <doc>
    <id>1696</id>
    <completedYear/>
    <publishedYear>2023</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber>62</pageNumber>
    <edition/>
    <issue/>
    <volume/>
    <type>bachelorthesis</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2023-03-06</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">A Structured Classification and Evaluation of Current and Future Treatments for Systemic Lupus Erythematosus</title>
    <abstract language="eng">Systemic Lupus Erythematosus (SLE) is a heterogeneous autoimmune disease that has a variety of manifestations and is therefore difficult to find a treatment for. Several advances have occurred in the field of SLE drug discovery, especially since the publishing of the first Genome Wide-Associated Studies in 2005. More than one hundred loci were found to be involved in the disease. Subsequently, the treatments were aimed towards tackling the pathways that were found after the uses of modern genetic techniques. Historically, the FDA approved only two drugs for treatment until the approval of Belimumab in 2011. Ten years later, two more drugs were approved in the same year, with few more drugs expected to receive approval in the near future. This study aims to evaluate the efficacy of these future drugs in addition to the ones considered to be milestones in the treatment of SLE, finding Anifrolumab to be the most promising drug currently on the market for treatment of moderate to severe SLE and Obinutuzumab to be the drug to watch.</abstract>
    <identifier type="urn">urn:nbn:de:hbz:1383-opus4-16960</identifier>
    <enrichment key="opus.source">publish</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">true</enrichment>
    <licence>CC0 1.0 Universell - Gemeinfreiheit (Public Domain)</licence>
    <author>Ahmed Abdelazim</author>
    <collection role="institutes" number="">Fakultät Life Sciences</collection>
    <thesisPublisher>Hochschule Rhein-Waal</thesisPublisher>
    <thesisGrantor>Hochschule Rhein-Waal</thesisGrantor>
    <file>https://opus4.kobv.de/opus4-rhein-waal/files/1696/Abdelazim_Lupus.pdf</file>
  </doc>
  <doc>
    <id>1692</id>
    <completedYear/>
    <publishedYear>2023</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber>62</pageNumber>
    <edition/>
    <issue/>
    <volume/>
    <type>bachelorthesis</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2023-02-27</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>2023-02-14</thesisDateAccepted>
    <title language="eng">MESENCHYMAL STEM CELLS (MSC) IN BREAST CANCER TREATMENT: ADVANTAGES AND CHALLENGES OVER TRADITIONAL THERAPIES</title>
    <abstract language="eng">Breast cancer is one of the most prevalent and deadly malignancies in women globally, due to its aggressive behavior and poor response to traditional treatments. Despite the significant improvements in understanding of tumor therapies, efforts to treat patients with advanced cancer are still hampered by the size and heterogeneity of the tumor burden and the development of drug resistance. Therefore, the need for novel therapeutic strategies is essential.&#13;
Mesenchymal stem cells (MSCs) have been studied for a long time with encouraging results in the treatment of metastatic cancers, including breast cancer. The discovery of MSCs' therapeutic abilities to inhibit the growth of cancer, cause cell death, and trigger immune responses served as a catalyst for the development of bioengineered MSCs. The use of MSCs in cell therapy is the subject of numerous investigations now. &#13;
This thesis aimed to summarize the current knowledge on traditional breast cancer treatments and compare them to novel approaches based on MSCs usage. To this end, scientific publications retrieved from databases such as PubMed were selected considering specific inclusion/exclusion criteria and were extensively analyzed. Results obtained underline the potential applications of MSCs for breast cancer treatment, such as using MSCs as carriers of oncolytic viruses, suicide genes, and anticancer medicines to malignancies. Furthermore, challenges and limitations of several MSCs based treatments and MSCs control were evaluated and discussed based on ongoing clinical trials.</abstract>
    <identifier type="urn">urn:nbn:de:hbz:1383-opus4-16927</identifier>
    <enrichment key="opus.source">publish</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">true</enrichment>
    <licence>CC0 1.0 Universell - Gemeinfreiheit (Public Domain)</licence>
    <author>Olga Chentsova</author>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>MSC</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Mesenchymal stem cells</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Traditional cancer therapies breast cancer</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>BC</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Treatment</value>
    </subject>
    <collection role="institutes" number="">Fakultät Life Sciences</collection>
    <thesisPublisher>Hochschule Rhein-Waal</thesisPublisher>
    <thesisGrantor>Hochschule Rhein-Waal</thesisGrantor>
    <file>https://opus4.kobv.de/opus4-rhein-waal/files/1692/Chentsova_MSCs.pdf</file>
  </doc>
</export-example>
